Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland

Xerophthalmia Clinical Trial

Official title:

Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04636372
• Other study ID #: LXY-meibomian gland
• Status: Withdrawn
• Phase: N/A
• Start date: September 1, 2020
• Est. completion date: January 31, 2021

Study information

• Verified date: September 2020
• Source: Wenzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

200 participants at Eye Hospital of Wenzhou Medical University during September, 2020 to November, 2020 will be enrolled in this study. The meibomian gland related therapy are pulsed light therapy and meibomian gland hot compress massage.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 31, 2021
• Est. primary completion date: January 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Previously untreated patients with xerophthalmia

Exclusion Criteria:

• No history of ocular surgery and trauma
• Any eye diseases except xerophthalmia
• No treated for xerophthalmia before
• Successful completion of follow-ups

Related Conditions & MeSH terms

• Xerophthalmia

Intervention

Device:
• Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.

Other:
• Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yune Zhao

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The length of meibomian glands after the treatment.	Length in millimeters.	up to 2 months
Primary	The area of meibomian glands after the treatment.	Area in millimeters^2.	up to 2 months
Primary	The percentage of meibomian glands after the treatment.	Percentage of meibomian glands in %(area of meibomian glands (mm^2) and area of palpebral conjunctiva (mm^2) will be combined to report percentage of meibomian glands in %) are used to assess this outcome measure.	up to 2 months